#7 - Poseida Therapeutics Inc. (NASDAQ:PSTX)
The last gene editing stock on this list is another small-cap play. Poseida Therapeutics Inc. (NASDAQ: PSTX). Like Caribou Biosciences, Poseida focuses on using CAR-T technology to find a treatment for cancer. However, whereas Caribou is in clinical trials with treatments for forms of blood cancer, Poseida is addressing solid cell tumors.
Unlike many of the stocks on this list, 2022 was a great year for PSTX stock. The stock is up 88% in the last 12 months and 27% in 2023. And analysts surveyed by MarketBeat give the stock a 99% upside.
That being said, the company is years away from having a commercially available product and short interest in PSTX stock rose sharply in January 2023. Still, for investors who have a risk appetite for clinical-stage trial companies, Poseida is one for the watchlist.
About Poseida Therapeutics
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Read More - Current Price
- $2.73
- Consensus Rating
- Buy
- Ratings Breakdown
- 2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $15.00 (449.5% Upside)
If you're like many investors, you may understand the benefit of gene editing, but may not be sure how to research the science behind these companies. One way around that is to invest in an exchange-traded fund (ETF) that provides exposure to gene editing companies.
Fans of Cathie Wood may want to look at the ARK Genomic Revolution ETF (NYSEARCA: ARKG). This fund includes at least two companies (CRSPR Therapeutics and Vertex Pharmaceuticals) that are listed in this presentation.
Two additional options for investors are the Global X Genomics & Biotechnology (NYSEARCA: GNOM) and the Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA: PBE).
Whatever option you choose, you don't have to go it alone. MarketBeat provides an extensive library of tools that can help you research and keep track of all the stocks in your portfolio or on your watchlist. Many of these tools are free to any investor. And when you upgrade to a MarkeBeat All-Access membership, you'll enjoy a range of enhanced research tools including access to our stock screeners.
More Investing Slideshows:
